Logo image of CYTK

CYTOKINETICS INC (CYTK) Stock Price, Quote, News and Overview

NASDAQ:CYTK - Nasdaq - US23282W6057 - Common Stock - Currency: USD

39.48  +0.33 (+0.84%)

After market: 39.43 -0.05 (-0.13%)

CYTK Quote, Performance and Key Statistics

CYTOKINETICS INC

NASDAQ:CYTK (4/17/2025, 8:11:31 PM)

After market: 39.43 -0.05 (-0.13%)

39.48

+0.33 (+0.84%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High68.76
52 Week Low32.74
Market Cap4.67B
Shares118.41M
Float115.15M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)05-01 2025-05-01/amc
IPO04-29 2004-04-29


CYTK short term performance overview.The bars show the price performance of CYTK in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -10 -20

CYTK long term performance overview.The bars show the price performance of CYTK in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 -10 -20 -30 -40

The current stock price of CYTK is 39.48 USD. In the past month the price decreased by -8.4%. In the past year, price decreased by -41.55%.

CYTOKINETICS INC / CYTK Daily stock chart

CYTK Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 17.09 306.02B
AMGN AMGEN INC 13.99 149.08B
GILD GILEAD SCIENCES INC 22.68 130.32B
VRTX VERTEX PHARMACEUTICALS INC 1686.55 125.74B
REGN REGENERON PHARMACEUTICALS 12.34 61.56B
ARGX ARGENX SE - ADR 318.82 36.40B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 30.51B
ONC BEIGENE LTD-ADR N/A 24.89B
BNTX BIONTECH SE-ADR N/A 23.74B
NTRA NATERA INC N/A 20.02B
SMMT SUMMIT THERAPEUTICS INC N/A 18.15B
BIIB BIOGEN INC 7.2 17.36B

About CYTK

Company Profile

CYTK logo image Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The company is headquartered in South San Francisco, California and currently employs 498 full-time employees. The company went IPO on 2004-04-29. The firm is engaged in the commercialization of aficamten, a cardiac myosin inhibitor, and is being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive hypertrophic cardiomyopathy. The firm is also developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF); CK-586, a cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.

Company Info

CYTOKINETICS INC

350 Oyster Point Boulevard

South San Francisco CALIFORNIA 94080 US

CEO: Robert I. Blum

Employees: 423

Company Website: https://cytokinetics.com/

Investor Relations: https://ir.cytokinetics.com

Phone: 16506243000

CYTOKINETICS INC / CYTK FAQ

What is the stock price of CYTOKINETICS INC today?

The current stock price of CYTK is 39.48 USD. The price increased by 0.84% in the last trading session.


What is the ticker symbol for CYTOKINETICS INC stock?

The exchange symbol of CYTOKINETICS INC is CYTK and it is listed on the Nasdaq exchange.


On which exchange is CYTK stock listed?

CYTK stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for CYTOKINETICS INC stock?

27 analysts have analysed CYTK and the average price target is 80.58 USD. This implies a price increase of 104.1% is expected in the next year compared to the current price of 39.48. Check the CYTOKINETICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is CYTOKINETICS INC worth?

CYTOKINETICS INC (CYTK) has a market capitalization of 4.67B USD. This makes CYTK a Mid Cap stock.


How many employees does CYTOKINETICS INC have?

CYTOKINETICS INC (CYTK) currently has 423 employees.


What are the support and resistance levels for CYTOKINETICS INC (CYTK) stock?

CYTOKINETICS INC (CYTK) has a support level at 37.87 and a resistance level at 39.49. Check the full technical report for a detailed analysis of CYTK support and resistance levels.


Is CYTOKINETICS INC (CYTK) expected to grow?

The Revenue of CYTOKINETICS INC (CYTK) is expected to grow by 775.08% in the next year. Check the estimates tab for more information on the CYTK EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy CYTOKINETICS INC (CYTK) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does CYTOKINETICS INC (CYTK) stock pay dividends?

CYTK does not pay a dividend.


When does CYTOKINETICS INC (CYTK) report earnings?

CYTOKINETICS INC (CYTK) will report earnings on 2025-05-01, after the market close.


What is the Price/Earnings (PE) ratio of CYTOKINETICS INC (CYTK)?

CYTOKINETICS INC (CYTK) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.26).


What is the Short Interest ratio of CYTOKINETICS INC (CYTK) stock?

The outstanding short interest for CYTOKINETICS INC (CYTK) is 12.21% of its float. Check the ownership tab for more information on the CYTK short interest.


CYTK Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

CYTK Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to CYTK. Both the profitability and financial health of CYTK have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CYTK Financial Highlights

Over the last trailing twelve months CYTK reported a non-GAAP Earnings per Share(EPS) of -5.26. The EPS increased by 3.49% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -42.06%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%8.7%
Sales Q2Q%912.38%
EPS 1Y (TTM)3.49%
Revenue 1Y (TTM)145.27%

CYTK Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 82% to CYTK. The Buy consensus is the average rating of analysts ratings from 27 analysts.

For the next year, analysts expect an EPS growth of -11.25% and a revenue growth 775.08% for CYTK


Ownership
Inst Owners112.72%
Ins Owners0.44%
Short Float %12.21%
Short Ratio8.96
Analysts
Analysts82.22
Price Target80.58 (104.1%)
EPS Next Y-11.25%
Revenue Next Year775.08%